TAS-102 plus bevacizumab in metastatic colorectal cancer

被引：0
|
作者：
Colloca, Giuseppe A. [1 ]
Venturino, Antonella [1 ]
机构：
[1] Osped Civile Sanremo, Dept Oncol, I-18038 San Remo, Italy
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E226 / E226
页数：1
相关论文
共 50 条
  • [1] TAS-102 plus bevacizumab in metastatic colorectal cancer Reply
    Pfeiffer, Per
    Moller, Soren
    Winther, Stine Braendegaard
    Qvortrup, Camilla
    LANCET ONCOLOGY, 2020, 21 (05): : E227 - E227
  • [2] TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?
    Eng, Cathy
    LANCET ONCOLOGY, 2020, 21 (03): : 326 - 327
  • [3] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Sugiura, Kiyoaki
    Seo, Yuki
    Takahashi, Takayuki
    Tokura, Hideyuki
    Ito, Yasuhiro
    Tanaka, Motomu
    Kishida, Norihiro
    Nishi, Yusuke
    Onishi, Yoshihiko
    Aoki, Hikaru
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [4] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Kiyoaki Sugiura
    Yuki Seo
    Takayuki Takahashi
    Hideyuki Tokura
    Yasuhiro Ito
    Motomu Tanaka
    Norihiro Kishida
    Yusuke Nishi
    Yoshihiko Onishi
    Hikaru Aoki
    BMC Gastroenterology, 21
  • [5] A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
    Chen, Xiaochen
    Qiu, Huafeng
    Chen, Yunwang
    Wang, Mingxing
    Zhu, Pengfei
    Pan, Shuangyue
    Deng, Yaya
    Yang, Liu
    Chen, Zheling
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] TAS-102 in metastatic colorectal cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (01): : E18 - E18
  • [7] TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
    Liu, Cheng-Jiang
    Hu, Ting
    Shao, Ping
    Chu, Wu-Yang
    Cao, Yu
    Zhang, Feng
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2021, 2021
  • [8] Retrospective study of TAS-102 plus bevacizumab for patients with metastatic colorectal cancer in salvage therapy
    Hisamatsu, A.
    Ikusue, T.
    Toshima, H.
    Kobayashi, K.
    Shimada, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice
    Shin, Ji Eun
    Lim, Sung Hee
    Lee, Jeeyun
    Lim, Ho Yeong
    Park, Young Suk
    Kim, Seung Tae
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [10] TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice
    Shin, J. E.
    Cho, S.
    Lee, J.
    Kim, S. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1443 - S1443
12345